Friday, December 5, 2025

Beijing Meeting Could Signal New Diplomatic Gamble for North Korea

Kim Jong Un's upcoming visit to China marks a potential shift in North Korea's diplomatic strategy, responding to U.S.-South Korea ties.

Drone Deployment Over Pyongyang Sparks National Security Investigation in South Korea

A special investigation team has imposed a travel ban on Maj. Gen. Kim Yong Dae amid allegations of collusion compromising national security.

Lee Kang In Recovers Quickly, Back with PSG Ahead of Big Matches

Lee Kang In returns to PSG training after a minor injury, preparing for upcoming matches in Ligue 1 and UEFA Champions League.

Jin Joong Hwang

Author's Latest

GAME OVER: Samsung Biologics Declares War With ‘ExellenS’—A Standard That Kills All Biotech Competition

Samsung Biologics launches ExellenS in Europe, enhancing biopharmaceutical production with standardized quality and efficiency.

Samsung Biologics Targets Japan’s $12.3 Billion CDMO Market: What You Need to Know

Samsung Biologics expands in Japan, targeting top pharma firms with new CMO brand 'ExellenS' and enhancing production capabilities.

Lotte Biologics Unveils Dual-Site Strategy: A Game Changer for Global CDMO in 2027

Lotte Biologics aims to lead in the evolving biotech landscape with dual sites in the U.S. and South Korea, enhancing global supply chains.

From R&D to Global Blockbuster: Fexuclue Sparks a New Vision for Daewoong

Daewoong Pharmaceutical's Fexuclue achieves rapid success with innovative marketing and aims for significant growth in treating GERD.

The Next Trillion-Dollar Bet: Korean Pharma Invests in Immuno-Oncology, Targeting a $1 Trillion Global Market

Cho Yong-joon outlines Dongkoo Bio's transformation into a global healthcare leader, emphasizing convergence and innovative growth strategies.

New Obesity Pill Could End Wegovy’s Reign, Offering Faster and Safer Results

Ildong's ID110521156 shows promise as an affordable GLP-1 obesity drug with fewer side effects, aiming to transform the treatment landscape.

Samsung Bioepis Taps Harrow to Take Over U.S. Ophthalmic Drug Rights from Biogen

Samsung Bioepis partners with Harrow to sell ophthalmic treatments in the U.S., transferring rights from Biogen by 2025.

Rising Use of GLP-1 Drugs May Be Linked to Rare Pancreatitis Cases, Study Finds

Reports of acute pancreatitis linked to GLP-1 diabetes drugs surge in the UK, prompting investigations and conflicting academic findings.

UK Pours Billions Into Health Tech to Become a Life Sciences Superpower

The UK government aims to lead Europe's life sciences by 2030, investing heavily in health data and regulatory reforms to boost growth.

New Hope for Solid Tumors? Korean Biotech Starts Phase 1 Trial of Targeted Drug

Digmbio secures 12 billion KRW for clinical trials of cancer drug DM5167 and advances treatment for degenerative brain diseases.

AI Search on Safari: Apple Confirms It’s Exploring ChatGPT and Perplexity

Apple is considering integrating AI search engines into Safari, but Google remains the default due to a lucrative contract.

Tumors Shrinking, Hopes Rising: Voronoi’s VRN11 Shows Over 40% Tumor Reduction in Early Lung Cancer Trial

Voronoi's VRN11 shows promising anti-cancer efficacy in early trials, reducing tumors in resistant lung cancer patients without major side effects.

A New Era in Precision Oncology—Lunit Unveils 7 AI-Driven Cancer Studies at AACR 2025

Lunit will present AI biomarker studies at AACR 2025, focusing on rare cancers and improving treatment strategies using AI analysis.

FDA Ruling Paves Way for Pharmacy Substitution of Yuflyma for Humira

Celltrion's Yuflyma receives FDA approval for interchangeability with Humira, boosting market confidence and distribution in the U.S.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.